This Innovative Inhaler Aims to Cut Childhood Asthma Attacks in Half

Asthma is among the first causes of school absenteeism and pediatric hospitalization in the world. Although widely studied, this chronic disease remains difficult to anticipate in the youngest, whose symptoms can evolve quickly without being immediately taken care of. While conventional treatments are struggling to prevent crises, a recently tested inhaler may well change the situation.

most common chronic diseases in the world. However, young patients rarely benefit from the most effective treatments. In many countries, children with light asthma are prescribed exclusively salbutamol, a rescue medication intended to relieve immediate symptoms. This bronchodilator, although effective in the short term, does not prevent crises. He does not act on the inflammation of the respiratory tract, which remains the main cause of exacerbations.

In practice, this approach shows its limits. The World Health Organization recalls that asthma can cause severe complications even in so -called “little symptomatic” children, especially when crises are not anticipated or brawled upstream. This vulnerability is explained by increased dependence on adults to recognize the warning signs and administer treatments in time.

Faced with this situation, some specialists alert for several years to the need to adapt the pediatric protocols. The discrepancy with the recommendations for adults has become difficult to justify, while evidence accumulates in favor of preventive treatment from the first symptoms, even in the youngest.

The Budesonide-Formoterol inhaler divides crises by two among the youngest

A major study controlled by the Medical Research Institute of New Zealand recently highlighted the benefits of a combined inhaler in children. The clinical trial, baptized Care, followed 360 children aged 5 to 15 for a year, all suffering from light asthma. Half of them used a conventional salbutamol treatment. The other half received a new inhaler combining an anti-inflammatory corticosteroid (budesonide) with a long-lasting bronchodilator (formoterol).

The results, published in the journal The Lancet, are final. The group treated with the Budesonide-Formoterol inhaler recorded a 45% drop in the number of crises, an average rate of 0.23 attack per child per year against 0.41 for salbutamol. This efficiency proved to be constant on all the age groups tested, with a particularly marked response in boys and adolescents.

Professor Richard Beasley, director of the MINRZ and co-author of the study, believes that this advance could transform medical practices internationally. He emphasizes that this strategy automatically adapts the dose of corticosteroid to the severity of the symptoms, without exposing children to permanent preventive treatment. Another reassuring point, the growth, the pulmonary function and the general condition of the children have shown no adverse effects, even after a full year of use.

This clinical assessment confirms the results previously obtained in adults. She comes to fill a glaring lack of data concerning the youngest, often excluded from therapeutic tests.

An advance that could reduce inequalities in the world in the world

In a context where 113 million children worldwide live with asthma, the potential impact of such treatment goes beyond the medical framework. Asthma attacks entail millions of missed school days each year and weigh heavily on health systems, especially in low -resources. A treatment capable of preventing these exacerbations, while remaining simple to use and well tolerated, therefore represents a major opportunity.

The Asthma and Respiratory Foundation of New Zealand's medical director, Professor Bob Hancox, recalls that this type of inhaler is already widely recommended in adults. According to New Scientist, he salutes new data that demonstrates his safety in children from the age of five, believing that this could harmonize therapeutic practices between generations.

If international health authorities incorporate this data into the next directives, millions of young patients may benefit from a more preventive, less random approach and better suited to the dynamics of the disease. The punctual use of a combined inhaler could thus become a new standard, in particular in areas where medical monitoring remains irregular.

The dissemination of these results could also promote a broader production of these devices, improving their financial accessibility worldwide. Researchers at the origin of the study, such as the Mrinz team, hope that this discovery will encourage decision -makers to review the priorities for pediatric respiratory health. A therapeutic advance is not only measured by its clinical efficiency, but also to its ability to affect those who need it most.